000721005 000__ 05328cam\a2200481\i\4500
000721005 001__ 721005
000721005 005__ 20210515103403.0
000721005 006__ m\\\\\o\\d\\\\\\\\
000721005 007__ cr\cn\nnnunnun
000721005 008__ 130814t20132013dcua\\\\ob\\\\100\0\eng\d
000721005 020__ $$z0309265959
000721005 020__ $$z9780309265959
000721005 020__ $$a9780309265966$$qelectronic book
000721005 035__ $$a(CaPaEBR)ebr10863916
000721005 035__ $$a(OCoLC)880439901
000721005 040__ $$aCaPaEBR$$beng$$erda$$epn$$cCaPaEBR
000721005 05014 $$aRC311.1$$b.W67 2012eb
000721005 08204 $$a362.19699/5$$223
000721005 1112_ $$aWorkshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB$$d(2012 :$$cWashington, D.C.),$$jissuing body.
000721005 24510 $$aDeveloping and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis$$h[electronic resource] :$$bworkshop summary /$$cAnna Nicholson [and three others], Rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies.
000721005 264_1 $$aWashington, District of Columbia :$$bNational Academies Press,$$c[2013]
000721005 264_4 $$c©2013
000721005 300__ $$a1 online resource (170 pages) :$$billustrations (some color)
000721005 336__ $$atext$$2rdacontent
000721005 337__ $$acomputer$$2rdamedia
000721005 338__ $$aonline resource$$2rdacarrier
000721005 500__ $$a"Forum on drug discovery, development, and translation."--Cover.
000721005 500__ $$a"Workshop was held on July 31- August 1, 2012 in Washington, D.C.
000721005 504__ $$aIncludes bibliographical references (pages 111-113).
000721005 5050_ $$aLogistics, Supply, and Demand -- Financing of MDR TB SLDs -- Innovative Suggestions and Potential Solutions.
000721005 506__ $$aAccess limited to authorized users.
000721005 520__ $$aTo effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB) a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin) face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high quality medicines to more of the people who need them. This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review: To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks ; The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain ; What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S. President's Emergency Plan for AIDS Relief [PEPFAR]) ; The current allocation of responsibilities and roles of the private (including industry and nonprofit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration ; Identification of potential innovative solutions to the problem.
000721005 588__ $$aDescription based on print version record.
000721005 650_0 $$aMultidrug-resistant tuberculosis$$xPrevention$$vCongresses.
000721005 650_0 $$aBusiness logistics$$vCongresses.
000721005 650_0 $$aInternational cooperation$$vCongresses.
000721005 7001_ $$aNicholson, Anna,$$econtributor.
000721005 7102_ $$aInstitute of Medicine (U.S.).$$bForum on Drug Discovery, Development, and Translation,$$eissuing body.
000721005 7102_ $$aInstitute of Medicine (U.S.).$$bBoard on Health Sciences Policy,$$eissuing body.
000721005 77608 $$iPrint version:$$aWorkshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB$$tDeveloping and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis : workshop summary.$$dWashington, District of Columbia : National Academies Press, [2013]$$z9780309265959$$w(OCoLC)828139251
000721005 852__ $$bebk
000721005 85640 $$3ProQuest Ebook Central Academic Complete$$uhttps://univsouthin.idm.oclc.org/login?url=http://site.ebrary.com/lib/usiricelib/Doc?id=10863916$$zOnline Access
000721005 909CO $$ooai:library.usi.edu:721005$$pGLOBAL_SET
000721005 980__ $$aEBOOK
000721005 980__ $$aBIB
000721005 982__ $$aEbook
000721005 983__ $$aOnline